Moderna Poised for mFLUSIVA Launch as FDA Approves First mRNA-Based Flu Vaccine

Moderna Poised for mFLUSIVA Launch as FDA Approves First mRNA-Based Flu Vaccine

Wed, October 07, 2026

Moderna (NASDAQ: MRNA) secured a landmark regulatory victory this past week as the U.S. Food and Drug Administration approved mFLUSIVA (formerly mRNA‑1010), the nation’s first licensed seasonal influenza vaccine developed using mRNA technology. The FDA granted traditional approval for adults aged 50 to 64 and accelerated approval for those 65 and older, pending post‑marketing confirmatory studies.

This approval, issued August 5, 2026, marks a major milestone in Moderna’s diversification beyond its COVID‑19 franchise and represents the company’s fifth approved product. The breakthrough paves the way for mFLUSIVA to be supplied for the 2026‑2027 flu season in the U.S.

Regulatory Comeback and Global Pipeline Progress

This approval completes a significant regulatory turnaround: earlier in February, the FDA had issued a “refusal‑to‑file” letter for the vaccine due to deficiencies in the submission package, notably regarding comparator data and surrogate endpoints. Moderna responded with a revised strategy, proposing traditional approval for 50–64 years and accelerated approval for 65+, which the FDA accepted under priority review. Moderna then received a unanimous endorsement from the FDA advisory committee before securing full approval.

Meanwhile, Moderna continues to advance its global vaccine pipeline. The European Commission granted marketing authorization for its combined flu + COVID vaccine, mCOMBRIAX, in April 2026. Regulatory filings for mRNA‑1010 are currently under review in Europe, Canada, and Australia, with approvals expected to begin this year. Additionally, Moderna is awaiting regulatory guidance in the U.S. for its mRNA‑1083 (flu + COVID) combination candidate.

Stock Market Implications

Although Moderna’s current share price of $187.46—down 7.24% as of October 6—is not directly tied to this approval, the mFLUSIVA victory strengthens its product portfolio and enhances its commercial outlook ahead of the 2026‑27 influenza season. Investors may view the approval as a key de‑risking event that supports longer‑term growth potential.

What to Watch Next

  • Market rollout: Timing and volume of mFLUSIVA distribution in the U.S. leading up to the flu season.
  • Global approvals: Regulatory outcomes for mRNA‑1010 and mCOMBRIAX in Canada, Australia, and other markets.
  • Financial impact: Adoption rates, pricing, and contribution of mFLUSIVA to Moderna’s revenue outlook.
  • Pipeline catalysts: Upcoming data releases from late‑stage programs in oncology and rare diseases.

The approval of mFLUSIVA is a watershed moment for Moderna. As the biopharma seeks to broaden its commercial foundation and sustain momentum beyond COVID‑19, its first mRNA flu shot sets a new benchmark for the industry and offers a tangible path toward future growth.